Pune, India,March 2023/MRFR Press Release/- Market Research Future has published its -cooked research report on the global fill finish manufacturing market.
Advancement in fill finish manufacturing techniques and growing R&D in pharmaceutical industry are expected to boost the growth of the global fill finish manufacturing market at a CAGR of 10.82% during the forecast period 2022 to 2030.
The global fill finish manufacturing market is expected to register a CAGR of 10.82% during the forecast period and is expected to hit USD 21.27 billion by 2030.
Fill finish is the final manufacturing step in the overall drug manufacturing process. It comes after upstream bioprocessing as well as also takes place after downstream purification. Fill finish manufacturing includes aseptically filling biological drugs and medicine in any form such as liquid powder, emulsion, suspension & cartridge to containers and sealing them. The rising incidences of chronic diseases, growing R&D in the pharmaceutical industry, and advancement in fill finish manufacturing techniques are key driving factors for the global fill finish manufacturing market. However, high costs and difficult-to-install factors are hampering the growth of the global fill finish manufacturing market. Moreover, a rise in demand for fill finish manufacturing in emerging markets is likely to create growth opportunities for global market leaders.
MRFR recognizes the following companies as the key players in the global fill finish manufacturing market— Thermo Fisher Scientific Inc. (US), Cytiva (US), Fujifilm Holdings Corporation (Japan), OPTIMA Packaging Group GmbH (Germany), Curia Global, Inc. (US), Baxter (US), Becton, Dickinson, and Company (US), Aenova Group (Germany), SGD Pharma (France) and Groninger & co. GmbH (Germany).
The global fill finish manufacturing market has been divided based on product, modality and end user.
The market, based on product, has been segmented into consumables, instruments and semi-automated & manual machines. The consumables segment is further sub-segmented into prefilled syringes, vials, cartridges and others. The instruments segment is also sub-segmented into system machine and machine product.
Based on modality, the fill finish manufacturing market has been divided into recombinant proteins, monoclonal antibodies, vaccines, cell therapies, viral gene therapies, non-viral gene therapies and others.
The market, based on end user, has been segmented into contract manufacturing organizations, biotechnology & pharmaceutical companies and others.
Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Fill Finish Manufacturing Market Research Report
The global fill finish manufacturing market, based on region, has been divided into the North America, Europe, Asia-Pacific, and the Rest of the World. The North America market is further divided into: US, Canada and Mexico. The Europe fill finish manufacturing market has been segmented into Germany, France, the UK, Italy, Spain, and the rest of Europe. The fill finish manufacturing market in Asia-Pacific has been segmented into China, India, Japan, Australia, and the rest of Asia-Pacific.
The North Americas is expected to dominate the fill finish manufacturing market due to extensive research and development activities, advanced manufacturing of innovative biopharmaceutical and pharmaceutical products. Additionally, considerable growth of the biopharmaceutical industry in Canada, growing investment by global companies are also boosting the market.
Europe held a significant share in global fill finish manufacturing market. The patent expiry of key biologic products, growing incidences of chronic disorders and growing use of Single-use Disposable Systems (SUDS) and Single Use Systems (SUS) for aseptic fill finish are driving the fill finish manufacturing market in Europe.
Asia-Pacific is expected to be the fastest-growing market for in the global fill finish manufacturing market. This is due to the rising government support for the business establishment of key players, increase in the production of biologics in Japan and robust production of pharmaceutical drugs and export. The rise in the development and market availability of parenteral drug also further boosts the market in the Asia-Pacific region.
The fill finish manufacturing market in the rest of the world is growing slowly. This growth is due to improving healthcare facilities, supportive government regulations and increasing research activities in the region. Furthermore, global companies are expanding their R&D capabilities in the region through subsidiaries, supplementing the growth of the fill finish manufacturing market.
Key Findings of the Study